ArticleActa pharmacologica Sinica2026
Deeper delving Nav1.8 inhibitor Suzetrigine in chronic pain.
Article in Acta pharmacologica Sinica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic pain is a complex disorder but has no satisfactory therapeutic strategies, though its mechanisms have been extensively studied, including sodium channels such as Nav1.7 and Nav1.8. The Nav1.8 channel inhibitor Suzetrigine was approved for acute pain treatment by the FDA in 2025, while its effects in chronic pain are still not clear and remain to be further studied, considering the more complex mechanism of chronic pain. Recent studies using Suzetrigine on neuronal excitability of human dorsal root ganglion partially support its effects on chronic pain, while some case reports demonstrated discouraging effects, implying the insufficiency of solid evidence to support its effects in chronic pain and a long gap from clinical application, which may be warranted by further well-designed clinical trials. This Perspective highlighted some concerns for future studies about Suzetrigine in chronic pain.
Indexed as
Identifiers
42745014What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.